Synthetic Lethality

Known as: Lethality, Synthetic 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2016
0102020102016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
A synthetic lethal interaction is a type of genetic interaction where the disruption of either of two genes individually has… (More)
Is this relevant?
2016
2016
PAXX was identified recently as a novel nonhomologous end-joining DNA repair factor in human cells. To characterize its… (More)
Is this relevant?
2016
2016
ATR and CHK1 maintain cancer cell survival under replication stress and inhibitors of both kinases are currently undergoing… (More)
Is this relevant?
2015
2015
Human lung adenocarcinomas (LUAD) contain mutations in EGFR in ∼15% of cases and in KRAS in ∼30%, yet no individual… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
The mammalian target of rapamycin complex 1 (mTORC1) integrates multiple signals from growth factors, nutrients, and cellular… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
A major goal of personalized anti-cancer therapy is to increase the drug effects while reducing the side effects as much as… (More)
  • table 1
  • table 2
Is this relevant?
2014
2014
A major goal in cancer medicine is to find selective drugs with reduced side effect. A pair of genes is called synthetic… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2013
2013
Synthetic lethality is a rational approach to identify candidate drug targets for selective killing of cancer cells harboring… (More)
Is this relevant?
2013
2013
Synthetic lethality (SL) is a novel strategy for anticancer therapies, whereby mutations of two genes will kill a cell but… (More)
Is this relevant?
2010
2010
Synthetic lethal interaction between oncogenic Ha-ras and loss of PKC has been demonstrated. Recently, the authors reported that… (More)
Is this relevant?